Supplementary Methods

Formation of Primagrafts
Following intrafemoral injection, mice were monitored for engraftment by tail vein bleed.
Blood was red cell lysed (ammonium chloride) and analysed by flow cytometry on a BD FACSCanto II using anti human CD10, CD34 and CD19 and anti-mouse CD45 antibodies (BD Biosciences, Oxford, UK), Once peripheral blood ALL levels reached >30%, mice were euthanised and spleens were removed and resuspended in RPMI 1640 plus 10% foetal bovine serum (FBS) . All spleens were >80% ALL cells as assessed by flow cytometry.
Gene Expression Microarray
RNA extracted from PreB 697 shCBP and shNEG cells on three separate occasions was ran on the Affymetrix U133 Plus 2.0 platform by Source Bioscience. Raw data was processed using R software and the GC Robust Multi-Array Average (gcrma) package to obtain expression values, hgu133plus2.db package to annotate gene probes and limma package to carry out differential gene expression analysis. Probe quality was determined by assessment of the normalised expression data and principal component analysis (PCA) and probes with low variation or low signal across arrays were removed. Genes were considered to be significantly differentially expressed where the p value was <0.05 and the fold change between groups was >2. Ingenuity pathway analysis (IPA) was carried out using QIAGEN's IPA software (Qiagen, Manchester, UK). Table S2 . List of TaqMan® assay probes (Applied Biosystems) RNA samples isolated from PreB 697 shCBP and shNEG on three separate occasions were analysed using the Affymetrix U133 Plus 2.0 platform. Data was normalised and genes whose expression was significantly altered in shCBP compared to shNEG control were identified.
Twenty eight genes in total were found to be significantly differentially expressed in CREBBP knockdown cells compared to control (Grey boxes greater expression, white boxes lower expression than control). Ingenuity pathway analysis (IPA) predicted that, based on the Figure S1 . CREBBP knockdown in PreB 697 cells has no effect on sensitivity to common ALL chemotherapies.
PreB 697 cells with stable CREBBP knockdown were assessed for sensitivity to drugs commonly used in ALL therapy; daunorubicin, vincristine, methotrexate and 6'-thioguanine, compared to isogenic control, by alamar blue drug sensitivity assay over 96 hours. CREBBP knockdown cells showed no differential sensitivity to any of the drugs tested. GI50 values, mean ±SD; daunorubicin shCBP 10.4nM ±1.5 versus shNEG 11.3nM ±0.52; p=0.4, vincristine shCBP 0.3nM ±0.02 versus shNEG 0.3nM ±0.04; p=0.07, methotrexate shCBP 9.4nM ±1.6 versus shNEG 9.8nM ±1.8; p=0.7 and 6-thioguanine shCBP 2.4µM ±0.58 versus shNEG 2.6µM ±0.32; p=0.6. Histograms show mean ±SD (N=3). Figure S2 . CREBBP knockdown in Ras wild type MHH-CALL-2 cells has no effect on p-ERK expression or sensitivity to the benchmark MEKi U0126
Ras wild type MHH-CALL-2 cells were assessed for expression of p-ERK and basal ERK by western blotting (A). Both control and siCBP transfected cells showed no expression of p-ERK.
MHH-CALL-2 cells with transient CREBBP knockdown were assessed for sensitivity to the benchmark MEKi U0126 and showed no differential sensitivity compared to control cells (B).
GI50 values, mean ±SD; siCBP 6.3µM ±1.2 versus control 4.9µM ±0.54; p=0.6. Histogram shows mean ±SD (N=3).
